Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Year of publication
- 2023 (11) (remove)
Document Type
- Journal article (11) (remove)
Language
- English (11) (remove)
Keywords
- 77-LH-28-1 (1)
- AGP (1)
- Analytical Quality by Design (1)
- Burkholderia pseudomallei Mip (1)
- Candida albicans (1)
- Candida auris (1)
- MYCNv (1)
- Mip inhibitor (1)
- PPIase (1)
- T-shaped π–π stacking (1)
- Xanomeline (1)
- acid value (1)
- amber light (1)
- anisotropy (1)
- antifungal drug (1)
- azobenzenes (1)
- bitopic hybrid ligands (1)
- capillary electrophoresis (1)
- charged aerosol detector (1)
- cyclodextrins (1)
- decafluoroazobezene (1)
- design of experiments (1)
- enantiomers (1)
- ephedrine (1)
- epitope mapping (1)
- ester value (1)
- fatty acids (1)
- fluorescence polarization (1)
- fluorescence resonance energy transfer (1)
- gastrointestinal (1)
- high throughput screening (1)
- in vitro dissolution methods (1)
- in vitro dissolution testing (1)
- in vivo dissolution (1)
- iodine value (1)
- ketamine (1)
- magnesium stearate (1)
- muscarinic acetylcholine receptors (1)
- neuroblastoma cell (1)
- norepinephrine transporter (1)
- oral bioavailability (1)
- oral drug absorption (1)
- peptide stapling (1)
- perfluoroarylation (1)
- photocontrol (1)
- polysorbate 80 (1)
- positron emission tomography (1)
- proteasome system (1)
- protein binding (1)
- quantitative 1H NMR (1)
- red fruit oil (1)
- saponification Value (1)
- saturation transfer difference NMR (1)
- structure–activity relationships (1)
- sympathetic nervous system (1)
- synthesis (1)
- ultrafiltration (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (11) (remove)
Formation of the Aurora-A–MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be `undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A–MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A–MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders.